Biomarker research in breast cancer

Clinical Journal of Oncology Nursing

Volumn 14, Issue 6, 2010, Pages 771-783

  Maxwell, Cathy ^a  

^a La Cesta Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952472109     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/10.CJON.771-783     Document Type: Article

References (95)

1. Abraham, B.K., Fritz, P., McClellan, M., Hauptvogel, P., Athelogou, M., & Brauch, H. (2005). Prevalence of CD44+/ CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clinical Cancer Research, 11, 1154-1159.
2. Aldhous, P. (2000). Genomics: Beyond the book of life. Nature, 408, 894-896. doi: 10.1038/35050235
3. Al-Hajj, M., Becker, M.W., Wicha, M., Weissman, I., & Clarke, M.F. (2004). Therapeutic implications of cancer stem cells. Current Opinion in Genetics and Development, 14, 43-47. doi: 10.1016/j.gde.2003.11.007
4. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., & Clarke, M.F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983-3988. doi: 10.1073/pnas.0530291100
5. Anderson, W.F., Chatterjee, N., Ershler, W.B., & Brawley, O.W. (2002). Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Research and Treatment, 76, 27-36.
6. Andreetta, C., Puppin, C., Minisini, A., Valent, F., Pegolo, E., Damante, G.,. Puglisi, F. (2009). Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Annals of Oncology, 20, 265-271. doi: 10.1093/annonc/mdn592
7. Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., McNamara, G.,. Cole, R.J. (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clinical Cancer Research, 12, 5615-5621. doi: 10.1158/1078-0432.CCR-06-0169
8. Bardou, V.J., Arpino, G., Elledge, R.M., Osborne, C.K., & Clarke, G.M. (2003). Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. Journal of Clinical Oncology, 21, 1973-1979. doi: 10.1200/JCO.2003.09.099
9. Baselga, J., Zambetti, M., Llombart-Cussac, A., Manikhas, G., Kubista, E., & Steger, G.G. (2009). Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology, 27, 526-534. doi: 10.1200/JCO.2007.14.2646
10. Berry, D.A., Cirrincione, C., Henderson, I.C., Citron, M.L., Budman, D.R., Goldstein, L.J.,. Winer, E.P. (2006). Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA, 295, 1658-1667.
11. Bordeleau, L., Panchal, S., & Goodwin, P. (2010). Prognosis of BRCA-associated breast cancer: A summary of evidence. Breast Cancer Research Treatment, 119, 13-24. doi: 10.1007/s10549-009-0566-z
12. Bristol-Myers Squibb. (2010). Ixempra® (ixabepilone) [Package insert]. Princeton, NJ: Author.
13. Byar, D.P., Sears, M.E., & McGuire, W.L. (1979). Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. European Journal of Cancer, 15, 299-310. doi: 10.1016/0014-2964(79)90041-0
14. Cardoso, F., Piccart-Gebhart, M., van't Veer, L., Rutgers, E., & the TRANSBIG Consortium. (2007). The MINDACT trial: The first prospective clinical validation of a genomic tool. Molecular Oncology, 1, 246-251. doi: 10.1016/j.molonc.2007.10.004
15. Chung, C.H., Bernard, P.S., & Perou, C.M. (2002). Molecular portraits and the family tree. Nature Genetics, 32(Suppl.), 533-540. doi: 10.1038/ng1038
16. Cobleigh, M.A., Bitterman, P., Baker, J., Cronin, M., Liu, M.L., Borchik, R.,. Shak, S. (2003). Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughput RT-PCR assay of paraffin-embedded tumor tissues [Abstract 3415]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=104115
17. Colomer, R., Montero, S., Lluch, A., Ojeda, B., Barnadas, A., Casado, A.,. Lloveras, B. (2000). Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clinical Cancer Research, 6, 2356-2362.
18. Coon, J.S., Marcus, E., Gupta-Burt, S., Seelig, S., Jacobson, K., Chen, S.,. Preisler, H.D. (2002). Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clinical Cancer Research, 8, 1061-1067.
19. Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009). Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Annals of Oncology, 20, 862-867. doi: 10.1093/annonc/mdn710
20. Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C.,. Hayes, D.F. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine, 351, 781-791. doi: 10.1056/NEJMoa040766
21. Cristofanilli, M., Hayes, D.F., Budd, G.T., Ellis, M.J., Stopeck, A., Reuben, J.M.,. Terstappen, L.W. (2005). Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of Clinical Oncology, 23, 1420-1430. doi: 10.1200/JCO.2005.08.140
22. Deemarsky, L.Y., & Chernomordikova, M.F. (1970). Combination chemotherapy in the management of breast cancer metastases. Cancer, 26, 771-779. doi: 10.1002/1097-0142(197010)26:4<771::AID-CNCR2820260405>3.0.CO;2-Y
23. Donegan, W.L., Sugarbaker, E.D., Handley, R.S., & Watson, F.R. (1970). The management of primary operable breast cancer: A comparison of time-mortality factors after standard, extended, and modified radical mastectomy. Proceedings-National Cancer Conference, 6, 135-143.
24. Dowsett, M., & Dunbier, A.K. (2008). Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clinical Cancer Research, 14, 8019-8026. doi: 10.1158/1078-0432.CCR-08-0974
25. Dowsett, M., Houghton, J., Iden, C., Salter, J., Farndon, J., A'Hern, R.,. Baum, M. (2006). Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to oestrogen receptor, progesterone receptor, EGF receptor, and HER2 status. Annals of Oncology, 17, 818-826. doi: 10.1093/annonc/mdl016
26. Dressler, L.G., Berry, D.A., Broadwater, G., Cowan, D., Cox, K., Griffin, S.,. Hayes, D.F. (2005). Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. Journal of Clinical Oncology, 23, 4287-4297. doi: 10.1200/JCO.2005.11.012
27. Early Breast Cancer Trialists' Collaborative Group. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet, 365, 1687-1717. doi: 10.1016/S0140-6736(05)66544-0
28. Eitan, R., Michaelson-Cohen, R., Levavi, H., & Beller, U. (2009). The counseling and management of young healthy BRCA mutation carriers. International Journal of Gynecological Cancer, 19, 1156-1159.
29. Elledge, R.M., Green, S., Pugh, R., Allred, D.C., Clark, G.M., Hill, J.,. Osborne, C.K. (2000). Estrogen receptor (ER) and progesterone receptor (PgR), by ligand binding assay compared with ER, PgR, and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. International Journal of Cancer, 89, 111-117. doi: 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W
30. Esteban, J., Baker, J., Cronin, M., Liu, M.L., Llamas, M.G., Walker, M.G.,. Shak, S. (2003). Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue [Abstract 3416]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=104527
31. Franco, A., Col, N., & Chlebowski, R.T. (2004). Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: A meta-analysis [Abstract]. Journal of Clinical Oncology, 22, 539.
32. Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M.,. Larsimont, D. (2002). Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Annals of Oncology, 13, 1036-1043. doi: 10.1093/annonc/mdf252
33. Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M.,. Dontu, G. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-567. doi: 10.1016/j.stem.2007.08.014
34. Gong, Y., Booser, D.J., & Sneige, N. (2005). Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer, 103, 1763-1769. doi: 10.1002/cncr.20987
35. Grann, V.R., Troxel, A.B., Zojwalla, N.J., Jacobson, J.S., Hershman, D., & Neugut, A.I. (2005). Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer, 103, 2241-2251. doi: 10.1002/cncr.21030
36. Hall, J.M., Friedman, L., Guenther, C., Lee, M.K., Weber, J.L., Black, D.M., & King, M.C. (1992). Closing in on a breast cancer gene on chromosome 17q. American Journal of Human Genetics, 50, 1235-1242.
37. Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S.,. Bast, R.C., Jr. (2007). ASCO 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25, 5287-5312. doi: 10.1200/JCO.2007.14.2364
38. Hayes, D.F., Thor, A., Dressler, L., Weaver, D., Broadwater, G., Goldstein, L.,. Berry, D. (2006). HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344 [Abstract 510]. Retrieved from http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/510
39. Hayes, D.F., Thor, A.D., Dressler, L.G., Weaver, D., Edgerton, S., Cowan, D.,. Berry, D.A. (2007). HER2 and response to paclitaxel in node-positive breast cancer. New England Journal of Medicine, 357, 1496-1506. doi: 10.1056/NEJMoa071167
40. Horak, C.E., Lee, F.Y., Xu, L., Galbraith, S., & Baselga, J. (2009). High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis [Abstract]. Journal of Clinical Oncology, 27, 3587.
41. Hwang-Verslues, W.W., Chang, K.J., Lee, E.Y., & Lee, W.H. (2008). Breast cancer stem cells and tumor suppressor genes. Journal of the Formosan Medical Association, 107, 751-766. doi: 10.1016/S0929-6646(08)60188-6
42. Ignatiadis, M., Georgoulias, V., & Mavroudis, V. (2008). Circulating tumors in breast cancer. Current Opinion in Obstetrics and Gynecology, 20, 55-60. doi: 10.1097/GCO.0b013e3282f22b2e
43. Joensuu, H., Kellokumpu-Lehtinen, P.L., Bono, P., Alanko, T., Kataja, V., Asola, R.,. Isola, J. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New England Journal of Medicine, 354, 809-820. doi: 10.1056/NEJMoa053028
44. Kandl, H., Seymour, L., & Bezwoda, W.R. (1994). Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. British Journal of Cancer, 70, 739-742.
45. Kar, S., Fan, J., Smith, M.J., Goedert, M., & Amos, L.A. (2003). Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO Journal, 22, 70-77. doi: 10.1093/emboj/cdg001
46. Knoop, A.S., Knudsen, H., Balslev, E., Rasmussen, B.B., Overgaard, J., Nielsen, K.V.,. Ejlertsen, B. (2005). Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology, 23, 7483-7490. doi: 10.1200/JCO.2005.11.007
47. Liu, R., Wang, X., Chen, G.Y., Dalerba, P., Gurney, A., & Hoey, T. (2007). The prognostic role of gene signature from tumorigenic breast-cancer cells. New England Journal of Medicine, 356, 217-226. doi: 10.1056/NEJMoa063994
48. Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A.M., Gillet, C.,. Sotiriou, C. (2007). Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through genomic grade. Journal of Clinical Oncology, 25, 1239-1246. doi: 10.1200/JCO.2006.07.1522
49. Ma, X.J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, E.,. Sgroi, D. (2008). A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clinical Cancer Research, 14, 2601-2608. doi: 10.1158/1078-0432.CCR-07-5026
50. MacGrogan, G., Rudolph, P., de Mascarel, I., Mauriac, L., Durand, M., & Avril, A. (2003). DNA topoisomerase IIa expression and the response to primary chemotherapy in breast cancer. British Journal of Cancer, 89, 666-671. doi: 10.1038/sj.bjc.6601185
51. Mass, R.D., Press, M.F., Anderson, S., Cobleigh, M.A., Vogel, C.L., Dybdal, N.,. Slamon, D.J. (2005). Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clinical Breast Cancer, 6, 240-246. doi: 10.3816/CBC.2005.n.026
52. Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S.,. Uhr, J. (2004). HER-2 gene amplification can be acquired as breast cancer progresses. Proceedings of the National Academy of Sciences of the United States of America, 101, 9393-9398.
53. Muss, H.B., Thor, A.D., Berry, D.A., Kute, T., Liu, E.T., Koerner, F.,. Barcos, M. (1994). c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New England Journal of Medicine, 330, 1260-1266. doi: 10.1056/NEJM199405053301802
54. National Comprehensive Cancer Network. (2010a). Clinical practice guidelines in breast cancer: Breast cancer [v.1.2010]. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf
55. National Comprehensive Cancer Network. (2010b). Genetic/familial high-risk assessment: Breast and ovarian [v.1.2010]. Retrieved from http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf
56. Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z.,. Perou, C.M. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research, 10, 5367-5374. doi: 10.1158 /1078-0432.CCR-04-0220
57. Oldenhuis, C.N.A.M., Oosting, S.F., Gietema, J.A., & de Vries, E.G.E. (2008). Prognostic versus predictive value of biomarkers in oncology. European Journal of Cancer, 44, 946-953. doi: 10.1016/j.ejca.2008.03.006
58. O'Malley, F.P., Chia, S., Tu, D., Shepherd, L.E., Levine, M.N., Huntsman, D.G.,. Pritchard, K.I. (2006, December). Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5) [Abstract 38]. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX.
59. Oncotype DX. (2010). Clinical summary. Retrieved from http://www.oncotypedx.com/HealthcareProfessional/ClinicalSummary.aspx?Sid=4
60. Paik, S., Hazan, R., Fisher, E.R., Sass, R.E., Fisher, B., Redmond, C.,. King, C.R. (1990). Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erB-2 protein overexpression in primary breast cancer. Journal of Clinical Oncology, 8, 103-112.
61. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M.,. Wolmark, N. (2003). Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14 [Abstract]. Breast Cancer Research and Treatment, 82, A16.
62. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., & Wolmark, N. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine, 351, 2817-2826. doi: 10.1056/NEJMoa041588
63. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M.,. Wolmark, N. (2005, May). Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [Abstract 510]. Retrieved from http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/510
64. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W.,. Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology, 24, 3726-3734. doi: 10.12 00/JCO.2005.04.7985
65. Paradiso, A., Mangia, A., Chiriatti, A., Tommasi, S., Zito, A., Latorre, A.,. Lorusso, V. (2005). Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Annals of Oncology, 16(Suppl. 4), iv14-iv19. doi: 10.1093/annonc /mdi902
66. Perou, C.M., Sørlie, T., Eisen, M., van de Rijn, M., Jeffery, S.S., & Rees, C.A. (2000). Molecular portraits of human breast tumors. Nature, 406, 747-752. doi: 10.1038/35021093
67. Press, M., Bernstein, L., Sauter, G., Zhou, J.Y., Eiermann, W., & Pienkowski, T. (2005, December). Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting [Abstract 1045]. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX.
68. Pritchard, K.I., Messersmith, H., Elavathil, L., Trudeau, M., O'Malley, F., & Dhesy-Thind, B. (2008). HER-2 and topoisomerase II as predictors of response to chemotherapy. Journal of Clinical Oncology, 26, 736-744. doi: 10.1200/JCO.2007.15.4716
69. Pusztai, L. (2007). Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Annals of Oncology, 18(Suppl. 12), xii15-xii20. doi: 10.1093/annonc/mdm534
70. Pusztai, L. (2008). Current status of prognostic profiling in breast cancer. Oncologist, 13, 350-360. doi: 10.1634/theoncologist.2007-0216
71. Ravdin, P.M., Green, S., Dorr, T.M., McGuire, W.L., Fabian, C., Pugh, R.P.,. Belt, R.J. (1992). Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. Journal of Clinical Oncology, 10, 1284-1291.
72. Robinson, B., Sica, G.L., Liu, Y.F., Rohan, T.E., Gertler, F.B., Condeelis, J.S., & Jones, J.G. (2009). Tumor microenvironment of metastasis in human breast carcinoma: A potential prognostic marker linked to hematogenous dissemination. Clinical Cancer Research, 15, 2433-2441. doi: 10.1158/1078-0432.CCR-08-2179
73. Ross, J.S. (2009a). Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News and Perspectives, 22(2), 93-106. doi: 10.1358/dnp.2009.22.2.1334452
74. Ross, J.S. (2009b). Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Advances in Anatomic Pathology, 16, 204-215.
75. Ross, J.S., Hatzis, C., Symmans, W.F., Pusztai, L., & Hortobagyi, G.N. (2008). Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist, 13, 477-493. doi: 10.1634/theoncologist.2007-0248
76. Rouzier, R., Rajan, R., Wagner, P., Hess, K.R., Gold, D.L., Stec, J.,. Pusztai, L. (2005). Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 102, 8315-8320.
77. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., & McGuire, W.L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 9, 177-182.
78. Slamon, D.J., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., & Pawlicki, M. (2006, December). BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [Abstract LBA 52]. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX.
79. Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., & Botstein, D. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America, 100, 8418-8423. doi: 10.1073/pnas.0932692100
80. Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., & Delorenzi, M. (2006). Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute, 98, 262-272. doi: 10.1093/jnci/djj052
81. Sparano, J.A., & Paik, S. (2008). Development of the 21-gene assay and its application in clinical practice and clinical trials. Journal of Clinical Oncology, 26, 721-728. doi: 10.1200/JCO.2007.15.1068
82. Tanner, M., Isola, J., Wiklund, T., Erikstein, B., Kellokumpu-Lehtinen, P., & Malmström, P. (2006). Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. Journal of Clinical Oncology, 24, 2428-2436. doi: 10.1200/JCO.2005.02.9264
83. U.S. Food and Drug Administration. (2010). FDA oncology drug approval. Endpoints, effectiveness, and approval. Retrieved from http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm103366.pdf
84. Vahdat, L. (2008). Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist, 13, 214-221. doi: 10.1634/theoncologist.2007-0167
85. van de Vijver, M.J., Mooi, W.J., Wisman, P., Peterse, J.L., & Nusse, R. (1988). Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene, 2, 175-178.
86. van't Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A., Mao, M.,. Friend, S.H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530-536. doi: 10.1038/415530a
87. Viale, G., Rotmensz, N., Maisonneuve, P., Bottiglieri, L., Montagna, E., Luini, A., & Colleoni, M. (2009). Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: Prognostic implications of EGFR immunoreactivity. Breast Cancer Treatment and Research, 116, 317-328. doi: 10.1007/s10549-008-0206-z
88. Voelker, R. (2009). Promising test flags BRCA mutations in populations of Hispanic women. JAMA, 301, 1326-1327.
89. Widakowich, C., Dinh, P., de Azambuja, E., Awada, A., & Piccart-Gebhart, M. (2008). HER-2 positive breast cancer: What else beyond trastuzumab-based therapy? Anticancer Agents in Medicinal Chemistry, 8, 488-496.
90. Willsher, P.C., Beaver, J., Pinder, S., Bell, J.A., Ellis, I.O., Blamey, R.W., & Robertson, J.F. (1996). Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Research and Treatment, 40, 251-255.
91. Wolff, A.C., Hammond, M.E.H., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J.,. Hayes, D.F. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology, 25, 118-145. doi: 10.1200/JCO.2006.09.2775
92. Wu, S., Chasalow, S., Lee, H., Xu, L., Paul, B., Mokliatchouk, O.,. Clark, E. (2007). Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients [Abstract 2525]. Retrieved from http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/2525
93. Wyckoff, J.B., Wang, Y., Lin, E.Y., Li, J.F., Goswami, S., & Stanley, E.R. (2007). Direct visualization of macrophage-assisted tumor cell motility and intravasation in mammary tumors. Cancer Research, 67, 2649-2656. doi: 10.1158/0008-5472.CAN-06-1823
94. Zardawi, S.J., O'Toole, S.A., Sutherland, R.L., & Musgrove, E.A. (2009). Dysregulation of Hedgehog, Wnt, and Notch signaling pathways in breast cancer. Histology and Histopathology, 24, 385-398.
95. Zidan, J., Dashkovsky, I., Stayerman, C., Basher, W., Cozacov, C., & Hadary, A. (2005). Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. British Journal of Cancer, 93, 552-556. doi: 10.1038/sj.bjc.6602738